VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of$ 0.40. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -5%. A quarter ago, it was expected that this company would post a loss of$ 0.41 per share when it actually produced a loss of $0.35, delivering a surprise of 14.63%. Over the last four quarters, the company h ...